NCT05050500View on ClinicalTrials.gov

The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

January 30, 2026

Conditions
Myocardial InfarctionDiabete Type 2Glucose Intolerance
Interventions
DRUG

Dapagliflozin 10mg/Tab

patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months

DRUG

Placebo

patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.

Trial Locations (1)

266042

RECRUITING

Mengmei Li, Qingdao

All Listed Sponsors
lead

Qingdao Central Hospital

OTHER